Ken Griffin
CBIO

Ken Griffin’s Crescent Biopharma CBIO Stock Holding History

Ken Griffin’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,593
Closed -$304K – 13173
2025
Q3 		$304K Buy
+25,593
New +$340K ﹤0.01% 10340
2024
Q2 		– Sell
-99
Closed -$10.3K – 14693
2024
Q1 		$29.7K Buy
99
+20
+25% +$5.97K ﹤0.01% 12705
2023
Q4 		$18.6K Buy
+79
New +$12.3K ﹤0.01% 12679
2023
Q3 		– Sell
-21
Closed -$3.59K – 14593
2023
Q2 		$3.59K Buy
+21
New +$3.52K ﹤0.01% 13680
2023
Q1 		– Sell
-503
Closed -$113K – 14998
2022
Q4 		$152K Buy
+503
New +$74.2K ﹤0.01% 10589
2022
Q3 		– Sell
-108
Closed -$6K – 12983
2022
Q2 		$6K Sell
108
-17
-14% -$1.26K ﹤0.01% 12662
2022
Q1 		$14K Sell
125
-838
-87% -$98.3K ﹤0.01% 13328
2021
Q4 		$138K Buy
963
+431
+81% +$78.2K ﹤0.01% 12374
2021
Q3 		$117K Sell
532
-536
-50% -$114K ﹤0.01% 12676
2021
Q2 		$247K Buy
1,068
+929
+668% +$236K ﹤0.01% 11719
2021
Q1 		$42K Sell
139
-1,222
-90% -$438K ﹤0.01% 12964
2020
Q4 		$512K Buy
1,361
+186
+16% +$65.2K ﹤0.01% 8096
2020
Q3 		$360K Sell
1,175
-1,437
-55% -$549K ﹤0.01% 7828
2020
Q2 		$982K Buy
2,612
+791
+43% +$224K ﹤0.01% 5862
2020
Q1 		$415K Sell
1,821
-874
-32% -$334K ﹤0.01% 6762
2019
Q4 		$1.43M Sell
2,695
-1,324
-33% -$717K ﹤0.01% 4964
2019
Q3 		$1.73M Buy
4,019
+239
+6% +$154K ﹤0.01% 4715
2019
Q2 		$4.5M Sell
3,780
-3,607
-49% -$4.31M ﹤0.01% 3251
2019
Q1 		$9.2M Sell
7,387
-580
-7% -$664K ﹤0.01% 2175
2018
Q4 		$7.54M Sell
7,967
-534
-6% -$643K ﹤0.01% 2227
2018
Q3 		$12.2M Sell
8,501
-6,030
-41% -$9.12M 0.01% 1879
2018
Q2 		$23.4M Buy
14,531
+2,905
+25% +$5M 0.01% 1174
2018
Q1 		$18.9M Buy
11,626
+7,495
+181% +$15.6M 0.01% 1169
2017
Q4 		$6.94M Buy
4,131
+3,547
+607% +$4.69M ﹤0.01% 2101
2017
Q3 		$817K Buy
584
+361
+162% +$424K ﹤0.01% 4599
2017
Q2 		$249K Buy
+223
New +$184K ﹤0.01% 6209

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Ken Griffin's CBIO Position: Q4 2025 in Review

Ken Griffin sold out of Crescent Biopharma (CBIO) in Q4 2025, closing a stake of 25,593 shares — an estimated $304K sold.

Ken Griffin first reported a position in CBIO in Q2 2017 and held it in 26 quarters. The position peaked at $23.4M in Q2 2018. 58 funds tracked by Wall St. Rank hold CBIO as of Q4 2025.

  • Ken Griffin reported no remaining Crescent Biopharma position as of Q4 2025 after selling out during the quarter.
  • Ken Griffin sold 25,593 Crescent Biopharma shares in Q4 2025, an estimated $304K.
  • Ken Griffin first reported a position in Crescent Biopharma in Q2 2017 and held it in 26 quarters.
  • Ken Griffin's Crescent Biopharma position peaked at $23.4M in Q2 2018.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.